NasdaqCM - Delayed Quote USD

INmune Bio, Inc. (INMB)

10.84

+0.22

(+2.07%)

At close: April 25 at 4:00 PM EDT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for INMB

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

TFFP TFF Pharmaceuticals, Inc.

3.0500

+3.39%

ANVS Annovis Bio, Inc.

13.60

+6.75%

AVXL Anavex Life Sciences Corp.

3.3900

-0.59%

SAVAW Cassava Sciences, Inc.

0.3101

+40.89%

LBPH Longboard Pharmaceuticals, Inc.

19.25

-2.53%

CGEM Cullinan Therapeutics, Inc.

19.25

+1.91%

ANIX Anixa Biosciences, Inc.

2.9800

-6.29%

LTRN Lantern Pharma Inc.

5.46

+1.49%

INAB IN8bio, Inc.

1.0400

-1.89%

BNTC Benitec Biopharma Inc.

6.94

+3.27%